Novo Nordisk A/S (NYSE:NVO) Shares Sold by Perfromance Wealth Partners LLC

Perfromance Wealth Partners LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 79.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,953 shares of the company’s stock after selling 127,184 shares during the period. Perfromance Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $2,749,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Natixis Advisors LLC boosted its holdings in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the last quarter. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter worth about $4,066,000. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S in the 4th quarter worth about $86,000. Finally, Zions Bancorporation N.A. boosted its holdings in Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Up 2.9 %

NVO stock opened at $80.95 on Wednesday. The firm has a market cap of $363.25 billion, a PE ratio of 26.20, a PEG ratio of 0.84 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm’s 50 day moving average price is $97.15 and its 200-day moving average price is $116.47. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.